AIM: To introduce the possible benefits of the positron-emission tomography (PET)/computed tomography (CT) with 18F-3'-deoxy-3'-fluorothymidine (18F-FLT) in patients with orofacial carcinomas and its impact to patient management. MATERIALS AND METHODS: Thirty-six patients with orofacial squamous cell carcinomas underwent 18F-FLT-PET/CT during radiotherapy. Examinations were performed after administration of 18F-FLT (1.8 MBq/kg) including full-diagnostic CT. Analysis of the radiotherapy effect was performed with possible prospect of repeated and focused irradiation. RESULTS: Complete absence of 18F-FLT uptake was found in 20 patients, thus complete response to radiotherapy was reported. Persistence of focal 18F-FLT uptake was observed in 16 patients; in 11 patients, the measured activity was only mild. In five patients, a higher level of 18F-FLT uptake was measured and additional irradiation was performed in defined regions. Repeated follow-up proved complete regression 18F-FLT uptake. CONCLUSION: It was possible to assess the effect of radiotherapy with the use of 18F-FLT-PET/CT and findings are suitable for radiation dose-escalation planning.

• MeSH
• Adult MeSH
• Image Interpretation, Computer-Assisted MeSH
• Middle Aged MeSH
• Humans MeSH
• Head and Neck Neoplasms diagnostic imaging   pathology   radiotherapy   MeSH
• Positron Emission Tomography Computed Tomography methods   MeSH
• Fluorine Radioisotopes * MeSH
• Retrospective Studies MeSH
• Aged MeSH
• Carcinoma, Squamous Cell diagnostic imaging   pathology   radiotherapy   MeSH
• Thymidine * MeSH
• Treatment Outcome MeSH
• Check Tag
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Male MeSH
• Aged MeSH
• Female MeSH
• Publication type
• Journal Article MeSH

BACKGROUND: Low-grade gliomas (LGG) of the brain have an uncertain prognosis, as many of them show continuous growth or upgrade over the course of time. We retrospectively investigated the role of positron emission tomography with 3'-deoxy-3'-[18F]fluorothymidine (FLT-PET) in the prediction of overall survival and event free survival in patients with untreated LGG. No such information is yet available in the literature. MATERIAL AND METHODS: Forty-one patients with previously untreated LGG underwent 55 FLT-PET investigations during their follow-up because of subjective complaints, objective worsening of clinical conditions, equivocal findings or progression on magnetic resonance imaging. The time interval before referral for neurosurgical or radiation treatment was considered to be event free survival, the interval until death as overall survival, respectively. Standardized uptake values (SUV) were measured, and a 3-point scale of subjective assessment was also applied. ROC analysis was used to define cut-off values. The log rank test was used for comparison of Kaplan-Meier survival curves. RESULTS: Eight patients (a total of 9 FLT-PET studies performed) died during follow-up. Progression leading to referral to therapy was recorded in 24 patients (a total of 33 FLT-PET studies). With a cut-off value of SUV(mean) = 0.236, a median overall survival of 1.007 days was observed in the test positive subgroup while median overall survival for the test negative subgroup was not achieved (p = 0.0002), hazard ratio = 17.6. Subjective assessment resulted in hazard ratio 11.5 (p = 0.0001). Only marginal significance (p=0.0562) was achieved in prediction of event free survival. CONCLUSIONS: Increased FLT uptake in previously untreated patients with LGG is a strong predictor of overall survival. On the other hand, prediction of event free survival was not successful in our cohort, probably because of high prevalence of patients who needed treatment due to symptoms caused by a space-occupying lesion without respect to the proliferative activity of the tumour.

• MeSH
• Dideoxynucleosides diagnostic use   MeSH
• Adult MeSH
• Glioma pathology   MeSH
• Middle Aged MeSH
• Humans MeSH
• Positron-Emission Tomography * MeSH
• Disease-Free Survival MeSH
• Aged MeSH
• Neoplasm Grading MeSH
• Check Tag
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Male MeSH
• Aged MeSH
• Female MeSH
• Publication type
• Journal Article MeSH
• Research Support, Non-U.S. Gov't MeSH

Existence cyklotronu a PET centra ÚJV Řež, a.s., v Masarykově onkologickém ústavu umožňuje výzkumníkům z RECAMO a Masarykova onkologického ústavu zapojit se do výzkumu, vývoje a využití nových radiofarmak včetně látek označených krátce žijícími pozitronovými zářiči (zejména [11C]). V současnosti zde vstupuje do I. fáze klinického hodnocení [11C]-značený tracer L-[methyl-11C]methionin a na oddělení nukleární medicíny jsou prováděny skeny s jinými PET radiofarmaky než fluordeoxyglukózou. Spolupráce by měla pokračovat i nadále a v budoucnu vyústit ve zpřístupnění více možností pro PET zobrazování v České republice.

The existence of the cyclotron & PET centre of ÚJV Řež, a.s., at Masaryk Memorial Cancer Institute allows the Masaryk Memorial Cancer Institute and RECAMO researchers to engage in the research, development and application of new radiopharmaceuticals including compounds labelled by short-living positron emitters (especially [11C]). Currently, a [11C]-labelled tracer, L-[methyl-11C]methionine, is entering phase I clinical evaluation, and scans with PET radiopharmaceuticals other than fluorodeoxyglucose are performed at the Department of Nuclear Medicine. Continued cooperation will bring new possibilities for PET in the Czech Republic in the future.

• Keywords
• L-[methyl-11C]methionin, [18F]fluorid sodný, [18F]fluorocholin, 3‘-deoxy-3‘[18F]fluorothymidin,
• MeSH
• Choline analogs & derivatives   diagnostic use   MeSH
• Dideoxynucleosides diagnostic use   MeSH
• Sodium Fluoride diagnostic use   MeSH
• Humans MeSH
• Methionine diagnostic use   MeSH
• Neoplasms * MeSH
• Positron-Emission Tomography * methods   MeSH
• Radiopharmaceuticals * diagnostic use   MeSH
• Fluorine Radioisotopes diagnostic use   MeSH
• Check Tag
• Humans MeSH
• Publication type
• Research Support, Non-U.S. Gov't MeSH

Hybridní zobrazovací metoda pozitronové emisní tomografie (PET) a počítačové tomografie (CT) představuje kombinaci funkčního a morfologicko-anatomického celotělového zobrazování. Záměrem autorů je podat ucelený přehled o základních principech PET, CT a hybridního zobrazování a o nejdůležitějších klinických indikacích. Těžiště publikace »Klinické PET a PET/CT« je v onkologické problematice, která tvoří většinu indikací k hybridnímu vyšetření. Kromě vyhledávání ložisek maligních nádorů, stagingu a kontroly terapeutického efektu zvolené léčby je pozornost věnována epileptologii, kardiologii a vyhledávání zánětlivých ložisek. Nakladatelství Galén děkuje Nemocnici Na Homolce za spolupráci a podporu při vydání této publikace.

• MeSH
• Fluorodeoxyglucose F18 diagnostic use   MeSH
• Clinical Medicine methods   MeSH
• Medical Oncology methods   MeSH
• Positron-Emission Tomography MeSH
• Tomography, Emission-Computed MeSH
• Publication type
• Monograph MeSH

• Conspectus
• Patologie. Klinická medicína
• NML Fields
• radiologie, nukleární medicína a zobrazovací metody

18F-Labelled compounds as active substances of radiopharmaceuticals are used for imaging in positron emission tomography (PET) in nuclear medicine. The radiosynthesis of PET radiopharmaceuticals is based on nucleophilic substitution with F- in a precursor. The synthesis is demonstrated on 3?-deoxy-3?-[18F]fluorothymidine.

• MeSH
• Dideoxynucleosides chemical synthesis   MeSH
• Financing, Organized MeSH
• Positron-Emission Tomography methods   MeSH
• Radiopharmaceuticals chemical synthesis   MeSH
• Thymidine analogs & derivatives   MeSH

Studium přípravy 3´- deoxy ´- (18F) fluorothymidin (18F) FLT a nalezení vhodného prekuzoru pro syntézu ( 18F) FLT). Vývoj metod kontroly kvality (18F)FLT, především kontroly radiochemické čistoty a chemické čistoty syntetizovaného produktu. Provedení úvodní biodistribuční studie včetně zobrazení distribuce na PET kameře.; Study of the 3´- deoxy-3´-(18F) fluorothymidine (FJFLT) preparation and finding a suitable synthesis precursor including the synthesis parameters optimization. Completion of the study of an irradiation target for sufficient production of fluorine. Development of methods of (18F) FLT quality control, above all of the radiochemical and chemical purity of the synthesized product. Performing the introductory biodistribution study including the distribution visualizing on a PET camera.

• MeSH
• Biopharmaceutics MeSH
• Chemistry, Pharmaceutical MeSH
• Drug Compounding MeSH
• Quality Control MeSH
• Thymidine analogs & derivatives   MeSH

• Conspectus
• Farmacie. Farmakologie
• NML Fields
• farmacie a farmakologie
• chemie, klinická chemie
• farmacie a farmakologie
• NML Publication type
• závěrečné zprávy o řešení grantu IGA MZ ČR